Insecticides (India) Limited — Investor Meet, 15-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Insecticides India Limited reported revenue of ₹627 crore for Q2 FY '25, down from ₹696 crore YoY. However, EBITDA rose to ₹90 crore, reflecting a YoY increase of 9%, while EBITDA margin improved to 14.3%. Profit After Tax (PAT) leaped 16% to ₹61 crore. For the half-year, revenue stood at ₹1,284 crore, with EBITDA at ₹128 crore and PAT at ₹111 crore, marking a notable YoY increase of 34%. The product mix revealed a focus on premium products, which constituted 68% of B2C sales.

2. **Future Outlook and Growth Drivers**: Management emphasized a strong outlook for the upcoming Rabi season, driven by good reservoir levels and favorable weather conditions potentially benefiting agrochemical demand. Initiatives around premiumization and new product launches remain central to the company's growth strategy, alongside continued improvements in production efficiency and supply chain management.

3. **Order Book and Operational Updates**: The management indicated recent challenges, with some sales returns primarily from herbicide products amounting to about ₹35-40 crore due to abnormal weather patterns. Nevertheless, there are positive signs of recovery in B2B and exports, forecasting stronger performance in the second half.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts inquired about sales returns impacting overall revenue, to which management confirmed returns for herbicides primarily due to weather disruptions.

- **Market Position**: When questioned about competitive dynamics and raw material pricing, management expressed confidence in navigating potential challenges while highlighting sustained premium product demand.

- **Operational Challenges**: Questions regarding inventory levels showed that management anticipates only minor sales returns and believes there will be no significant stock issues.

- **Capex**: Management reiterated the importance of disciplined capital allocation amid expanding R&D efforts, without delving into specific capex figures.

- **Strategic Priorities**: Discussions revealed a commitment to innovation and expansion, particularly through beneficial acquisitions like Kaeros, aimed at enhancing the product portfolio.

5. **Market Updates**: There were no significant regulatory changes reported, but management indicated favorable market conditions expected to drive growth.

6. **Strategic Focus Areas**: A consolidation around premiumization is evident, with strong emphasis on R&D, expansion of the Maharatna product line, and improved training initiatives for the sales team to enhance market penetration.

7. **Investor Insight**: Given the solid profitability trends and strategic initiatives in place, the current financial health and growth trajectory suggest maintaining a ‘buy’ position. The optimistic outlook for the second half combined with current product performance are positive indicators.